Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation

LINA PANG1,2, SHUYAN HAN1,2, YANNA JIAO1,2, SHANTONG JIANG1,2, XIRAN HE1,2 and PINGPING LI1,2

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute; 2Department of Integration of Chinese and Western Medicine, Peking University School of Oncology, Beijing 100142, P.R. China

Received January 9, 2017; Accepted March 3, 2017

DOI: 10.3892/ijo.2017.4014

Abstract. Macrophages play a pivotal role in tumor microenvironment. Bu-Fei Decoction (BFD) is a classical formula of traditional Chinese medicine (TCM) to alleviate lung cancer related symptoms, whether it has antitumor effect or could influence cancer microenvironment deserves further study. The aim of the present study was to examine the antitumor effect of BFD on non-small cell lung cancer (NSCLC), and to investigate the underlying mechanisms through tumor associated macrophages (TAMs). M2-polarized TAMs were induced by Phorbol 12-myristate 13-acetate (PMA) and interleukin 4 (IL-4). The antitumor activity of BFD in vitro was investigated in A549 and H1975 cells using MTT assay. The in vivo anticancer effect of BFD was evaluated in athymic nude mouse xenograft model. The invasive and migration properties of NSCLC cells were measured using Transwell. The protein expression was assessed using western blotting, ELISA and immunohistochemistry. The gene expression was examined using RT-PCR. TAMs was successfully established. Conditioned medium from TAMs increased cell proliferation, migration and invasion in NSCLC cells (p<0.05). BFD showed dose-dependent inhibitory effect on cell proliferation, migration and invasion abilities induced by TAMs. TAMs and rhIL-10 promoted the mRNA and protein expression of PD-L1 in NSCLC cells (p<0.01). Anti-IL-10 antibodies inhibited the elevated PD-L1 expression induced by TAMs. In vitro, the expression of PD-L1 and IL-10 was inhibited by BFD dose-dependently. In vivo, BFD suppressed A549 and H1975 tumor growth and decreased the expression of IL-10, PD-L1 and CD206. The results showed that TAMs play an important role in tumor progression of NSCLC, which was associated with tumor proliferation, migration, invasion and immunosuppression. Moreover, the antitumor mechanism of BFD is related to interruption of the link between TAMs and cancer cells by inhibiting the expression of IL-10 and PD-L1 in vitro and in vivo. Our results demonstrated BFD’s potential as a novel treatment for NSCLC.

Introduction

Lung cancer is the most frequently diagnosed cancer in men and the third most commonly diagnosed cancer in women throughout the world (1). Eighty to eighty-five percent of lung cancer are non-small cell lung cancer (NSCLCs) (2). The majority of lung cancer (57%) are diagnosed at advanced stage. Despite decades of bench and clinical research to attempt to improve outcome for NSCLC, the 5-year overall rate remains only ~21% (3). The existing therapies, including radiotherapy, chemotherapy and the emerging target therapy, are still unsatisfactory to improve outcomes for lung cancer patients (4). It is an urgent issue to achieve breakthrough in medical treatment on lung cancer.

Tumor microenvironment has attracted much attention in recent years. Macrophages are the main non-cancer cell components in tumor microenvironment, and often described as tumor-associated macrophages (TAMs) (5). Macrophages originate from blood monocytes, and there are two main classes of macrophages: classically activated macrophages (also called M1) and alternatively activated macrophages (M2) (6). When exposed to lipopolysaccharide (LPS) or
interferon-γ (IFN-γ), macrophages are polarized into M1 macrophages; whereas interleukin-4 (IL-4) or interleukin-13 (IL-13) exposure can polarize them into M2 macrophages (7). M1 macrophages generally exhibit microbicidal activity and have pro-inflammatory phenotype. In contrast, M2 macrophages are able to tune inflammatory responses and adaptive Th2 immunity (8). Solid tumors are often infiltrated with abundant macrophages, which resembles M2 macrophages that can produce high amounts of interleukin (IL)-10 and transforming growth factor-β (TGF-β), express scavenger receptors (CD204) and mannose receptor (CD206), and exhibit anti-inflammatory and tissue repair functions (9).

TAMs play an essential role in the complex process for coevolution and tumorigenesis in tumor microenvironment. Lee et al. showed that IL-10 mediated M2-polarized TAMs promoted renal cell carcinoma (RCC) growth through increasing BMP-6 expression (10). TLR4/IL-10 signaling increased the proliferation of cancer cells induced by M2-polarized TAMs, while TLR4 siRNA or neutralizing antibodies of TLR4 and IL-10 significantly reversed the increased growth (11). TAMs and their secreted cytokines (e.g., IL-10, TNF-α, TGF-β) or proteases were able to promote the migration and invasion of cancer cells in all aspects (12,13). Previous studies revealed that M2-polarized macrophages induced migration and invasion of human basal carcinoma cells and prostate cancer cells (14,15). TAMs also promoted tumor angiogenesis, proliferation and invasion in pancreatic cancer, and hepatocellular carcinoma (16-19). Indeed, removal of macrophages by genetic mutation, ablation of macrophage function or inhibition of macrophage infiltration into tumors successfully reduced tumor progression and metastasis in human breast carcinomas, and pulmonary metastatic cells (20,21). The establishment of macrophages contributed to progress of research to develop therapies that specifically target macrophages. These possible therapeutic agents are divided into three main aspects: inhibition of monocyte recruitment into tumors, eradication of resident macrophages already in tumors, and neutralization of key molecules of TAM release, such as CCL5 and VEGF (8,22-25). However, most of these therapeutic methods are still at the research stage.

In addition, IL-10 may promote cancer growth by suppressing macrophage function and enabling tumors to evade immunosurveillance (26). Kuang and his colleagues (27) observed that IL-10 secreted from activated monocytes strongly induced the expression of programmed cell death 1 (PD-L1) in an autocrine manner. PD-L1-positive monocytes induced T cell dysfunction, as defined by the presence of low cytotoxicity to tumor cells and a reduction in T cell proliferation targeted therapy aiming at IL-10 or PD-L1 may be an effective method for NSCLC. Whether IL-10 secreted from TAMs could regulate the expression of PD-L1 in NSCLC cells by paracrine way and whether BFD can interfere with the interaction between TAMs and tumor cells is still unknown.

Bu Fei decoction (BFD) is a classical formula of traditional Chinese medicine (TCM) in clinical setting for hundreds of years. It consists of six herbal Chinese medicines including Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Astragalus, Aster and Cortex Mori. BFD is a mixture of these herbal Chinese medicines in a certain proportion. BFD is widely used for improving lung functions, especially for the Qi deficiency. So it is to alleviate lung cancer related symptoms in oncology clinical context and has a good clinical effect. The team of Xia et al. (28,29) have devoted research effort on BFD on lung tissue of pulmonary fibrosis. They found that BFD could decrease the degree of alveolitis and pulmonary fibrosis decreased significantly, which was associated with reduced expression of α-SMA, MMP-9 and TIMP-1 and re-established the balance among these, then improved the abnormal metabolism of extracellular matrix. Nevertheless, there has been until now no systematic research to study BFD as a whole in lung cancer. In recent years, several studies found that many components of BFD possess antitumor effect. Research data showed that herbal extract from Astragalus could induce dendritic cell maturation, promote IFN-γ secretion and activate the antitumor effect of special cytotoxic T lymphocytes (CTLs) (30). Some research data show that Schisandrin B, one of the bioactive compounds from Schisandra chinensis, could suppress epithelial mesenchymal transform (EMT) in breast cancer both in vitro and in vivo, scavenged oxygen free radicals and inhibited the expression of VEGF (31,32). However, nothing is known on whether BFD possesses antitumor effect or it could influence tumor microenvironment in lung cancer. Therefore, the aim of the present study was to investigate the effects of BFD on TAMs and NSCLC in vitro and in vivo, to possibly clarify underlying mechanisms.

Materials and methods

Preparation of drugs. The component herbs of BFD used in this study are as follows, Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Astragalus, Aster and Cortex Mori, at a ratio of 3:2:1.8:4:2:2. Furthermore, Schisandra chinensis was treated with vinegar. Radix Rehmanniae Praeparata was used in the prescription. Aster is a honey-fried Chinese herb. The BFD granules used in the present study were purchased from Beijing Tcmages Pharmaceutical Co., Ltd. (Beijing, China). The quality of formula granules was monitored by Fourier transform infrared spectroscopy (FTIR) (Model IRPrestige-21; Shimadzu Corp., Kyoto, Japan). Prior to experiment, the formula granules were milled to powders and dissolved in distilled water to get a concentration of 1 g/ml crude drug, and then filtered through a 0.22-μm membrane (Millipore, Billerica, MA, USA). The concentrations of BFD in the study refer to the crude drug concentrations.

Reagents. Phorbol 12-myristate 13-acetate (PMA) and 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human IL-4 was purchased from R&D Systems (Minneapolis, MN, USA). Human Fc receptor binding inhibitor purified and anti-human IL-10 for neutralization were purchased from Sigma-Aldrich. BDF mice anti-human CD206 antibody (BD Pharmingen, 551135), anti-mannose receptor antibody (Abcam, ab64693), anti-PD-L1 antibody (Abcam, ab58810), anti-IL-10 antibody (Abcam, ab99689).
**Cell culture and differentiation.** Human NSCLC cell lines A549 and NCI-H1975 were purchased from the American Type Culture Collection (Manassas, VA, USA). Human monocytic leukemia U937 cells (RIKEN, RCB0435) were donated by Professor C. Wang, Peking University Health Science Center. Cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C and 5% CO₂.

U937 cells were seeded at a density of 5x10⁵ cells/well into 10-cm culture dishes with RPMI-1640 containing 10% FBS and 100 µg/ml PMA. After 24 h, the cells were washed with phosphate-buffered saline (PBS, pH 7.2) and incubated with IL-4 (20 ng/ml) for the indicated times. Then cells were washed with PBS and incubated with serum-free 1640 for 24 h. After 24-h serum starvation, cells were collected and used as M2-polarized TAMs, and the medium was collected and prepared as M2-polarized TAM-conditioned medium (TAM-CM). The supernatants and cells were collected and stored at -80°C until use.

**Morphological characterization and flow cytometry.** Morphological characterization of U937 cells and PMA-IL-4-treated U937 cells was acquired by phase-contrast microscopy. Cells were washed with PBS and resuspended in PBS. Cells were then incubated in Clear Back (human Fc receptor blocking reagent) (MBL, Nagoya, Japan) for 20 min followed by incubation with FITC-mouse anti-human CD206 (BD Biosciences) for 60 min on ice in the dark. After the final washing step, labeled cells were analyzed by flow cytometry (BD Accuri C6).

**Cell viability assay.** 5-diphenyltetrazolium bromide (MTT) assay was used to measure cell viability. Briefly, cells were plated in 96-well culture plates at the density of 5-10x10³ per well in complete medium. After 24-h incubation, cells were treated with BFD (0-80 mg/ml) in serum-free medium or TAM-CM for 24 h. Then the cells were incubated with 100 µl 0.5 mg/ml MTT at 37°C for 4 h, and the precipitate was dissolved in 150 µl dimethylsulfoxide (DMSO). After shaking for 10 min, the optical density at 570 nm was measured and the IC₅₀ value was calculated on the non-linear regression fit method by Graphpad Prism 5.0 software (San Diego, CA, USA).

**Transwell assay.** Cell migration and invasion were performed in 24-well plates using transwell chambers (Corning, NY, USA) fitted with a polyethylene terephthalate filter membrane with 8-µm pores. Cells (5x10⁴) were seeded in serum-free medium in the upper chamber (normal chamber for migration assay and matrigel-coated chamber for invasion assay). The lower chamber was filled with medium containing 10 or 20% FBS. After incubating for 24 h at 37°C, cells in the upper chamber were carefully removed with a cotton swab, and the cells that had traversed to reverse face of the membrane were cleaned and fixed in methanol, stained with crystal violet. Images were taken with a microscope and cells were counted under 5 randomly chosen fields.

**RNA extraction and quantitative real-time PCR.** Total RNA was extracted from cells using TRIzol reagent according to the manufacturer's instructions (Invitrogen Life Technologies). The concentration and quality of the extracted RNA were measured with a NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA). The first-strand cDNA was generated using the TransScript first-strand cDNA synthesis supermix (Transgen, Beijing, China) according to the manufacturer's instructions. Primers designed for PCR were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) and are shown below. The RT-PCR assay was performed using SYBR green qPCR supermix (Applied Biosystems Life Technologies, Foster City, CA, USA) in an ABI PRISM 7500 sequence detection system (Applied Biosystems Life Technologies). The PCR specific primers were 5'-GAC TTT AAG GGT TAC CTG GTG TG-3' (forward) and 5'-TCA CAT GCG CCT TGA TGT CTG-3' (reverse) for IL-10, 5'-GGA CAA GCA GTG ACC ATC AAG-3' (forward) and 5'-CCC AGA ATT ACC AAG TGA GTC CT-3' (reverse) for PD-L1, 5'-GGT GAA GGT CGG TGT GAA CG-3' (forward) and 5'-CTC CCT GCT GGA AGA TGG TG-3' (reverse) for GADPH. The conditions as shown below: 55°C for 10 min, followed by 40 cycles of 95°C for 30 sec, 55-59°C for 30 sec and 72°C for 42 sec. The fold changes of each gene were calculated using the ∆∆Ct (cycle threshold) method, and gene expression levels were normalized by GADPH.

**Western blotting.** The cells were plated in dishes at a density of 5x10⁵ cells/ml, which were treated with BFD (0-80 mg/ml) in serum-free medium or TAM-CM for 48 h. After the treatment, the cells were washed in PBS and lysed with RIPA lysis buffer (CWBio, Beijing, China). Total protein of tumor tissues was extracted as above. Protein concentrations were determined using the BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA). The samples corresponding to 20 µg of protein were boiled for 8-10 min, resolved on an 8-15% denatured SDS polyacrylamide gel, and transferred onto a PVDF membrane (Millipore, Bedford, MA, USA). After blocking non-specific binding sites for 1 h using 5% skim milk, the membranes were incubated with specific antibodies overnight at 4°C. The membranes were washed with TBST and incubated with a peroxidase-conjugated secondary antibody for 1 h. Visualization of the protein bands was accomplished using an Immobilon Western Chemiluminescent HRPS substrate (Millipore). ImageJ software was used to calculate the expression of each protein, which was normalized by β-actin.

**Regulation of PD-L1 expression.** In order to verify whether it was IL-10 in TAMs that regulated the expression of PD-L1 in NSCLC cells. TAM-CM with neutralizing mAbs against IL-10 (eBioscience) or recombinant human (rh) cytokines IL-10 was used instead of TAM-CM in the culture system, and PD-L1 expression was detected by western blotting as mentioned above. The level of IL-10 in culture supernatants was detected by ELISA, and concrete implementation method was in accordance with manufacturers specifications.

** Determination of antitumor effect in nude mice.** Female BALB/c nude mice (6-8-week-old) were obtained from Peking University Health Science Center (Beijing, China). The animals were kept under a specified pathogen-free (SPF) condition with a 12-h light/dark cycle and freely accessed autoclaved standard food and water. The animal experiment protocol was...
approved by Peking University Animals Research Committee and conducted in accordance with European community guidelines. Human NSCLC cell lines A549 (3x10⁶) or H1975 (3x10⁶) cells were suspended in 0.25 ml of PBS mixed 1:1 with Matrigel (BD Biosciences) and subcutaneously inoculated into the right flank of nude mice.

The daily dosage for nude mice was obtained based on the daily dosage for humans at 0.58 g/kg (equivalent to a crude drug dose of 1.23 g/kg) in clinical. After calculation using the human-mouse transfer formula, the dosage of BFD for nude mice was determined to be 30 and 60 g/kg, which were 2 and 4 times the anticipated clinical dosage, respectively. The human-mouse transfer formula: \( \text{Animal dose} = \frac{\text{Human dose} \times (\text{HK}_m / \text{AK}_m)}{\text{HK}_m} \), where \( \text{HK}_m \) and \( \text{AK}_m \) represent the \( K_m \) factor of human (Human \( K_m: 37 \)) and mouse (Mouse \( K_m: 3 \)) (33).

Tumor growth was measured with tumor volume by the following formula: tumor volume (mm\(^3\)) = \( 1/2 \times \text{length} \times \text{width}^2 \). When the tumors reached a size range of 50-100 mm\(^3\), the mice were randomly divided into 3 groups (n=8-10): control, BFD (30 g/kg) and BFD (60 g/kg). All the compounds were administered orally twice a day for consecutive 21 days, and then the tumor volume and body weight of the mice were measured every 3 days during the administration period.

At the end of study, blood was gained from the eyeballs of mice, and their tumors were removed and weighed after the animals were sacrificed. Tumor tissues were fixed in formalin for immunohistochemistry analysis or stored at -80°C for protein election.

**Statistical analysis.** The data were presented as the means ± SE of at least three separate experiments. All comparisons were analyzed with Student's two-tailed t-test, with \( p<0.05 \) considered statistically significant.

**Results**

**Successful induction of M2-polarized TAMs.** As shown in Fig. 1A, compared with native cells, PMA-IL-4 treated U937 cells attached to the culture dish and developed elongated macrophage-like projections. Western blotting and flow cytometry results (Fig. 1B and C) showed that the mannose
receptor CD206 was significantly higher than native cells (p<0.05). The mRNA and protein expression levels of IL-10 were obviously increased in PMA-IL-4 treated U937 cells (p<0.05) (Fig. 1C-E). The above results suggested that IL-4 (20 ng/ml) and PMA (100 ng/ml) successfully induced the alteration of classical macrophages to M2-polarized TAMs.

Coculture with M2-polarized TAMs increased the proliferation, migration and invasion of NSCLC cells. The coculture system between TAMs and NSCLC cells was established by culturing cancer cells in M2-polarized TAM-conditioned medium (TAM-CM). We next examined the effects of TAMs on NSCLC cell proliferation, migration and invasion. Compared with routine medium, coculture with TAMs significantly increased the cell viability in both H1975 and A549 cells. Cell survival rates were increased by 11.9% in H1975 and 24.3% in A549, p<0.01 (Fig. 2A).

TAMs significantly promoted more H1975 and A549 cell migration to the lower chamber. Compared with the control group, the number of migrated cells in TAM-CM was 454.5±23.49 and 494.1±60.18 in H1975 and A549 cells, respectively; whereas the corresponding cell number was 290.9±15.2 and 157.4±24.22, in the control group (p<0.001) (Fig. 2B).

The invasive ability of cancer cells in TAM-CM underwent similar alterations as the migratory ability. The number of invaded cells in TAM-CM was 197.6±8.617 and 590.3±96.52 in H1975 and A549 cells, compared to the cells in routine medium, with the invaded cell number of 115.0±4.402 and 319.6±52.36, respectively (p<0.05) (Fig. 2C).

Dose-dependent suppression of NSCLC cell proliferation, migration and invasion by BFD in TAM conditioned medium. NSCLC cell proliferation was reduced by BFD in a dose-dependent manner, especially in H1975 cells with an IC50 of 22.84 mg/ml in routine medium and 49.36 mg/ml in TAM-CM. The inhibition of A549 cells was relatively weak, the IC50 was 75.80 mg/ml in routine medium and 73.62 mg/ml in TAM-CM (Fig. 3A).

The number of migrated cells was reduced gradually BFD dose-dependently, and there was a significant difference in
Figure 3. Dose-dependent suppression of NSCLC cell proliferation, migration and invasion by BFD. (A) Cell proliferation was reduced by BFD. H1975: IC_{50}, 22.84 mg/ml (routine medium), IC_{50}, 49.36 mg/ml (TAM-CM); A549: IC_{50}, 75.80 mg/ml (routine 1640 medium), IC_{50}, 73.62 mg/ml (TAM-CM). (B) The numbers of migrated cell permeating septum were reduced by BFD. (C) The invasive ability of cells was decreased by BFD, \( p < 0.05 \), \( ^{*} p < 0.01 \), \( ^{**} p < 0.001 \) vs TAM-CM.
comparison to TAMs. The number of migrated H1975 cells was 368.0±30.65, 326.0±11.45 and 139.5±34.23 with BFD at dose of 5, 10 and 20 mg/ml, respectively, p<0.05. While for A549 cells, the number was 283.0±45.82, 178.1±33.06 and 150.7±25.48 with BFD at dose of 20, 40 and 80 mg/ml, respectively, p<0.05 (Fig. 3B).

Figure 4. IL-10 secreted from TAMs promotes PD-L1 expression on NSCLC cells. (A and B) The mRNA and protein expressions of PD-L1 in H1975 and A549 cells was increased by TAM-CM. (C) rhIL-10 promoted PD-L1 expression on cancer cells like TAM-CM. (D) Anti-IL-10 mAb gradually weakened the upregulation of PD-L1 on A549 and H1975 cells induced by TAM-CM. (E) The level of IL-10 in TAM-CM or rhIL-10 culture system was higher than the control group. (F) The level of IL-10 in TAM-CM with anti-IL-10 and cancer cell coculture system was greatly lower than the TAM-CM group, *p<0.05, **p<0.01, ***p<0.001.
The invasive ability of cancer cells was also decreased BFD dose-dependently. Compared with the TAM-CM, the number of invaded cells for H1975 cells was 153.1±12.44, 145.8±15.99 and 145.7±7.276 with BFD at dose of 5, 10 and 20 mg/ml, respectively, p<0.01. For A549 cells, the number was 300.0±87.8, 203.8±42.42 and 105.1±21.71 with BFD at dose of 20, 40 and 80 mg/ml, respectively, p<0.05 (Fig. 3C).

IL-10 secreted from TAMs promotes PD-L1 expression in NSCLC cells. Real-time PCR and western blotting showed that the mRNA and protein expression of PD-L1 were higher in cancer cells cocultured with M2-polarized TAMs than those in monoculture (Fig. 4A and B). Compared with the control group, the protein expression of PD-L1 in cancer cells cocultured with TAMs was increased ~3-fold in H1975 and 0.7-fold in A549.
in A549, respectively (p<0.001). mRNA level was increased 6.7-fold in H1975 and 1.432-fold in A549, in comparison with those of the control group (p<0.05).

We tested the expression of PD-L1 in cancer cells in rhIL-10 or TAM-CM with neutralizing mAbs against IL-10 instead of TAM-CM. As shown in Fig. 4C, compared with the control group, rhIL-10 promoted PD-L1 expression on A549 and H1975 cells like TAMs, and the difference was statistically significant (p<0.01). While TAM-CM with anti-IL-10 mAb gradually weakened the upregulation of PD-L1 on A549 and H1975 cells (p<0.05, Fig. 4D).

The level of IL-10 in TAM coculture system was higher than cancer cells in monoculture. The level of IL-10 was increased by 41.27% (p<0.05) in H1975 and 25.68% (p<0.001) in A549 coculture system, respectively. It was increased by 25.87% (p<0.05) in H1975 and 22.48% (p<0.05) in A549, respectively (Fig. 4E).

The level of IL-10 in TAM-CM with anti-IL-10 coculture system was greatly lower than the TAM-CM group. The level of IL-10 in H1975 treated with anti-IL-10 at a dose of 2.5, 5 and 10 µg/ml showed a 17.12 (p>0.05), 27.74 (p<0.05) and 33.62% (p<0.01) decrease, respectively. Similarly, IL-10 level in A549 decreased by 4.60 (p>0.05), 19.10 (p<0.01) and 32.85% (p<0.01) using 2.5, 5 and 10 µg/ml anti-IL-10 treatment (Fig. 4F). It was established that IL-10 secreted by TAMs induced PD-L1 expression in NSCLC cells.

**BFD reduces the expression of IL-10 and PD-L1 in vitro.** After cancer cells were treated with different doses of BFD, the protein and mRNA expression of PD-L1 in NSCLC cells cocultured with TAMs was gradually inhibited in comparison with the TAM-CM group. The protein expression of PD-L1 in H1975 treated with BFD at a dose of 5, 10 and 20 mg/ml showed a 25.92 (p<0.001), 71.32 (p<0.001) and 80.74% (p<0.001) decrease, respectively. Similarly, PD-L1 protein in A549 decreased by 28.64 (p<0.01), 36.49 (p<0.01) and 70.57% (p<0.001) using 20, 40 and 80 mg/ml BFD treatment (Fig. 5A). PD-L1 mRNA expression levels

![Figure 6. BFD suppresses A549 and H1975 tumor growth in xenograft mice.](image_url)

(A) The body weight was not decreased by BFD compared with the control group (p>0.05). (B) In H1975 xenograft mice, tumor volume and tumor weight was suppressed by BFD dose-dependently (p<0.05). (C) In A549 xenograft mice, the tumor volume and tumor weight was decreased by BFD dose-dependently (p<0.05), *p<0.05, **p<0.01, ***p<0.001.
in H1975 treated with BFD at a dose of 5, 10 and 20 mg/ml showed a 71.84 (p<0.05), 77.27 (p<0.05) and 91.97% (p<0.05) decrease, respectively. Similarly, PD-L1 mRNA expression in A549 was decreased by 34.71 (p<0.05), 54.30 (p<0.05) and 64.47% (p<0.01) using 20, 40, and 80 mg/ml BFD treatment (Fig. 5B).

PD-L1 in NSCLC cells induced by rhIL-10 was also inhibited BFD dose-dependently. Compared with the rhIL-10 group, PD-L1 in H1975 treated with BFD at a dose of 5, 10 and 20 mg/ml showed a 21.99 (p<0.001), 35.36 (p<0.001) and 80.28% (p<0.001) decrease, respectively. Similarly, PD-L1 in A549 decreased by 48.26 (p<0.001), 53.45 (p<0.001) and 55.16% (p<0.001) using 20, 40 and 80 mg/ml BFD treatment (Fig. 5C).

IL-10 in TAM coculture system was decreased by BFD dose-dependently. Compared with the TAM-CM group, IL-10 in H1975 treated with BFD at a dose of 5, 10 and 20 mg/ml showed a 26.01 (p<0.05), 33.89 (p<0.05) and 43.42% (p<0.05) decrease, respectively. Similarly, IL-10 in A549 decreased by 22.98 (p<0.01), 33.76 (p<0.001) and 42.21% (p<0.001) using 20, 40 and 80 mg/ml BFD (Fig. 5D).

BFD decreased IL-10 in NSCLC culture system induced rhIL-10 dose-dependently. Compared with the rhIL-10 group, IL-10 in H1975 treated with BFD at a dose of 5, 10 and 20 mg/ml showed a 12.93 (p<0.05), 23.46 (p<0.001) and 34.51% (p<0.01) decrease, respectively. IL-10 in A549 decreased by 11.2 (p<0.05), 21.44 (p<0.01) and 35.38% (p<0.05) using 20, 40 and 80 mg/ml BFD (Fig. 5E).

**BFD suppresses A549 and H1975 tumor growth in xenograft mice.** We evaluated the anticancer effect of BFD on female nude mice bearing A549 or H1975 tumors. Comparing BFD groups with the control group, there was no significant intergroup difference in body weight during the therapy (p>0.05) (Fig. 6A). In H1975 xenograft mice, BFD (30 g/kg) group decreased tumor volume and tumor weight to some extent, there was a statistical difference in comparison to the control group (p<0.05); BFD (60 g/kg) group decreased tumor volume and tumor weight to a great extent, and the difference was statistically significant (p<0.05) (Fig. 6B). In A549 xenograft mice, tumor volume and tumor weight slightly decreased by 30 g/kg BFD, there was no statistical difference (p>0.05). While tumor volume and tumor weight greatly decreased with 60 g/kg BFD compared with the control group (p<0.05) (Fig. 6C).

**BFD reduces PD-L1, IL-10 and CD206 protein expression in vivo.** BFD resulted in a downregulation of PD-L1, IL-10 and CD206 in A549 and H1975 tumor tissue dose-dependently. As shown in Fig. 7A, compared with the control group, BFD 30 and 60 g/kg resulted in a downregulation of PD-L1 in H1975 tumor tissue by 25.59 (p<0.001) and 38.39% (p<0.001), respectively. While for A549 tumor tissue, PD-L1 was decreased by 17.24 (p<0.01) in BFD 30 and 29.79% (p<0.001) in BFD 60 g/kg. IL-10 in H1975 tumor tissue was decreased by 51.66 (p<0.001) in BFD 30 g/kg and 62.44% (p<0.001) in BFD 60 g/kg. While for A549 tumor tissue, BFD 30 and 60 g/kg also resulted in a significant decrease in IL-10 by 28.87 (p<0.01) and 39.50% (p<0.01), respectively. BFD 30 and 60 g/kg resulted in a downregulation of CD206 in H1975 tumor tissue by 22.25 (p<0.001) and 47.21% (p<0.001), respectively. While for A549, CD206 was decreased by 43.73% (p<0.001) in BFD 30 g/kg and 60.82% (p<0.001) in BFD 60 g/kg.

The serum level of IL-10 was significantly lower BFD dose-dependently, compared with the control group (p<0.001) (Fig. 7B). Using IHC staining, PD-L1 and IL-10 were analyzed in all tumor specimens. PD-L1-positive cells were evenly scattered throughout the specimens, it was located primarily in the cytoplasm and membrane of tumor cells. IL-10 was also generally expressed in the cytoplasm of tumor cells. The above was consistent with the study of Geng et al (34). Representative IHC staining is shown in Fig. 7C.

**Discussion**

IL-10 and PD-L1 are two major immunosuppressor proteins associated with tumorigenesis and tumor progression. Tumor associated macrophages represent key regulators of the complex interplay between the immune system and cancer (35). As a classic compound of TCM, BFD is widely used to alleviate lung cancer related symptoms by improving lung functions and enhancing the body immunity. In our study, conditioned medium from TAMs promoted the expression of PD-L1 in NSCLC cells by secreting IL-10. Furthermore, IL-10 and PD-L1 was decreased by BFD in vitro and in vivo.

M2-polarized TAMs were established in vitro. Taniguchi et al (7) used PMA and IL-4 to treat U937 cells and obtained M2-polarized TAMs. We treated U937 cells as described above. M2-polarized TAMs were successfully induced and confirmed (Fig. 1). Tumor associated macrophage conditioned medium (TAM-CM) was collected and extracted, as described by Liu et al and Chen et al (11,36).

In the present study, TAMs significantly promoted the proliferation, migration and invasion of NSCLC cells, H1975 and A549, as expected (Fig. 2). The results suggested that TAMs provided a suitable microenvironment for tumor progression. Some cytokines may exist in the microenvironment of TAMs probably to promote tumor growth and metastasis. Previous studies also revealed that M2-polarized macrophages induced tumor proliferation, migration and invasion in hepatocellular carcinoma, human basal carcinoma cells, pancreatic cancer and prostate cancer cells (9,10,17). When NSCLC cells were treated with different doses of BFD, the abilities of cell proliferation, migration and invasion induced by TAMs were gradually decreased, and there was a significant difference in comparison to the TAM group (Fig. 3). Thus, we presumed BFD probably inhibited some target cytokine or protein secreted by TAMs, causing change of the tumor microenvironment and interruption of the interaction between TAMs and cancer cells. The next key work is to find target cytokines or protein associated with TAMs and BFD.

Immunosuppressive cytokines (e.g., IL-10 and TGF-β) or proteases secreted by TAMs probably play an important role in tumor progression. IL-10 may tune inflammatory responses and adaptive Th2 immunity, which strongly inhibits Th1 cytokines (IFN-γ) to exert antitumor effect, and the tumor progression is accelerated (37-39). As another important immunosuppressive protein, PD-L1 is a co-inhibitory molecule expressed generally on antigen-presenting cells and tumor cells (40). By binding
Figure 7. BFD reduces PD-L1, IL-10 and CD206 protein expression in vivo. (A) The administration of BFD resulted in a downregulation of PD-L1, IL-10 and CD206 protein expression in A549 and H1975 tumor tissue dose-dependently. (B) The serum level of IL-10 were significantly lower BFD dose-dependently. (C) Representative IHC staining of PD-L1 and IL-10, *p<0.05, **p<0.01, ***p<0.001.
to its receptor PD-1, which is mainly expressed in activated T cells, PD-L1 induces apoptosis, anergy, unresponsiveness, and exhaustion of T cells (41,42). We detected that the expression of PD-L1 was significantly increased in NSCLC cells when cocultured with TAMs (p<0.001) (Fig. 4A and B). Prior research has shown that PD-L1 expression was upregulated in HCC cells by macrophages. They also found a significant correlation between PD-L1 expression and TAM infiltration in 63 HCC tissues samples (43). Also, if we suppose some cytokines released from TAMs induced the overexpression of PD-L1 in cancer cells and activated relevant signal pathway. In order to find the target cytokine in TAM-CM, TAM-CM was replaced with rhIL-10 or TAM-CM with neutralizing mAbs against IL-10 in the culture system. The results showed that the expression of PD-L1 in cancer cells was related to the level of IL-10 in the culture system (Fig. 4C and D). It was probably IL-10 secreted by TAMs that regulated the expression of PD-L1 in tumor cells. Some studies showed that PD-L1 expression in tumor infiltrative macrophages could be upregulated through modulation of IL-10 autocrine/paracrine signaling in gliomas and HCC, leading to macrophages with immunosuppressive phenotype (27,44). We found the correlation between IL-10 secreted by TAMs and PD-L1 in NSCLC cells. Geng and colleagues (34) indicated that tumor-associated PD-L1 expression was correlated with IL-10 products in 40 pancreatic carcinoma samples. Moreover, they also found PD-L1 expression was significantly associated with poor tumor differentiation (p<0.01) and advanced tumor stage (p<0.01). Kuang et al (27) found that IL-10 regulated the PD-L1 expression in macrophages of hepatoma tissue, which was similar to our results. To the best of our knowledge, this study is the first to demonstrate the association between PD-L1 in cancer cells and IL-10 secreted by TAMs in NSCLC.

When NSCLC cells were treated with different doses of BFD, the expression of PD-L1 and IL-10 induced by TAMs was gradually inhibited in vitro, and the difference was statistically significant (Fig. 5). In addition, the administration of BFD resulted in a reduction in the expression of PD-L1, IL-10 and CD206 in tumor tissues (Fig. 7A). Overexpression of PD-L1 has been reported to correlate with poor prognosis in a number of human cancers, including breast cancer, kidney cancer, and NSCLCs (45). Blocking PD-L1 with a specific antibody improved specific T cell immunity, suggesting that PD-L1 limits the capacity of T cells to eliminate tumor cells (46). The concentration of IL-10 in serum of xenograft mice was significantly decreased by BFD dose-dependently (Fig. 7B). High IL-10 level in serum of xenograft mice was significantly decreased by administration of BFD resulting in a reduction in the expression of PD-L1 and IL-10 induced by TAMs. In our study, we constructed BFD with six kinds of single BFD components, Milkvetch root is a good immunomodulator (48-50). Milkvetch root suppresses the production of oxygen free radicals to reduce damage to the biomembrane (51). It also could regulate T-lymphocyte function, inhibit NF-κB activation, and control clinical symptoms in patients with lung cancer. We focused on the BFD regulation of immunosuppression in this investigation to explain its antitumor mechanism. Its antitumor effect is probably through downregulating the expression of PD-L1 and IL-10 in tumor environment of TAMs.

Our results found that BFD groups had no influence on body weight during the whole therapy (Fig. 6), but its long-term administration still needs further study. Besides, as a classic compound of TCM, BFD is probably a multi-targeted antitumor drug, proteomics may be helpful to find more target proteins of the drug action. Going further into the antitumor mechanism with proteomics is of great significance in the future. However, the validation by western blotting is required subsequently to proteomics. Pharmaceutical analysis in BFD extract is required in future study. In order to make our research comprehensive, we are currently conducting related clinical trials of BFD.

In conclusion, the authors showed that TAMs play an important role in tumor progression of NSCLC, which was associated with tumor proliferation, migration, invasion and immunosuppression. Moreover, the antitumor mechanism of BFD is related to interruption of the link between TAMs and cancer cells by inhibiting the expression of IL-10 and PD-L1 in vitro and in vivo. Our results demonstrated BFD’s potential as a novel treatment for NSCLC.

Acknowledgements

The authors would like to acknowledge Huirong Ding for his help with flow cytometry, Bin Dong for her help with IHC staining and Guo An for her help with animal experiment at the Central Laboratory of Peking University Cancer Hospital and Institute.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al (eds): SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, seer.cancer.gov/csr/1975_2013/ (based on November 2015 SEER data submission, posted to the SEER web site, April 2016).
3. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66: 271-289, 2016.
4. Gardiner RE, Jahangeer S, Forde P, Ariffin F, Bird B, Soden D and Hinchion J: Low immunogenicity in non-small cell lung cancer: do new developments and novel treatments have a role? Cancer Metastasis Rev 34: 129-144, 2015.
5. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M and Ley K: Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661, 2010.
6. Solinas G, Germano G, Mantovani A and Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065-1073, 2009.
7. Taniguchi K, Kikiji H, Okinaga T, Hashidate-Yoshida T, Shinou H, Ariyoshi W, Shimizu T, Tominaga K and Nishihara T: Essential role of lysophosphatidylcholine acyltransferase 3 in the induction of macrophage polarization in PMA-treated U937 cells. J Cell Biochem 116: 2860-2868, 2015.

8. Coffelt SB, Hughes R and Lewis CE: Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796: 11-18, 2009.

9. Zwaal G, Voegeli R, Schulze Osthoff K and Sorg C: A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 55: 295-304, 1987.

10. Lee JH, Lee GT, Woo SH, Ha YS, Kwon SJ, Kim WJ and Kim YJ: BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Int J Cancer 126: 1896-1903, 2010.

11. Liu C-Y, Xu J-Y, Shi X-Y, Huang W, Ruan T-Y, Xie P and Ding J-L: M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLK4/JL-1 signaling pathway. Lab Invest 93: 844-854, 2013.

12. Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y and Chen H: Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 74: 188-196, 2011.

13. Tjiu JW, Chen JS, Shun CT, Chen JS, Liao YH, Chu CY, Tsai TF, Chieh JC, Kuo KY, Liu CC, Liu CC, Ho CC, Hsu CR, Chang CC, et al: Essential role of lysophosphatidylcholine acyltransferase 3 on prostate cancer cell migration and invasion induced by tumor-associated macrophages. PLoS One 9: e99630, 2014.

14. Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.

15. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Shames DS, Beck AW, Barnett CC, Fleming JB and Brekken RA: A chemokine receptor antagonist inhibits recruited macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 55: 295-304, 1987.

16. Li CC, Hou YC, Yeh CL and Yeh SL: Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages. PLoS One 9: e99630, 2014.

17. Mellor AL and Munn DH: Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8: 74-80, 2008.

18. Fan Q-M, Jing Y-Y, Yu GF, Kou XR, Ye F, Gao L, Li R, Zhao QD, Yang Y, Lu ZH, et al: Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 1021-1027, 2008.

19. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78, 2004.

20. Lin EY, Nguyen AV, Russell RG and Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to metastatic disease. J Exp Med 193: 303-314, 2001.

21. Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA and Raes G: Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol 5: 489, 2014.

22. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE and Balkwill FR: A chemokine receptor agonist inhibits experimental breast tumor growth. Cancer Res 63: 8360-8365, 2003.

23. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE and Song K: Monocyte-depleted IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunothe 30: 831-838, 2007.
49. Li W, Sun YN, Yan XT, Yang SY, Song SB, Lee YM and Kim YH: NF-κB inhibitory activity of sucrose fatty acid esters and related constituents from *Astragalus membranaceus*. *J Agric Food Chem* 61: 7081-7088, 2013.

50. Chen X, May B, Di YM, Zhang AL, Lu C, Xue CC and Lin L: Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD: A systematic review of effect on BODE index and six minute walk test. *PLoS One* 9: e91830, 2014.

51. Wang T, Sun Y, Jin L, Xu Y, Wang L, Ren T and Wang K: Enhancement of non-specific immune response in sea cucumber (*Apostichopus japonicus*) by *Astragalus membranaceus* and its polysaccharides. *Fish Shellfish Immunol* 27: 757-762, 2009.